NEUEXCELL THERAPEUTICS
NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion. Our vision is to improve the quality of life of millions of patients worldwide who are suffering from neurodegenerative conditions by using the power of gene therapy to restore damaged neural tissue.
NEUEXCELL THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Diagnostics Medical
Founded:
2016-01-01
Address:
State College, Pennsylvania, United States
Country:
United States
Website Url:
http://www.neuexcell.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
10 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Content Delivery Network Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy DNS
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Curative
Curative is a leader in on-demand public health programs and infrastructure. We're building a healthier tomorrow, together.
NeoGenomics
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cowin Venture
Cowin Venture investment in Seed Round - Neuexcell Therapeutics
Oriza Seed Capital (Oriza Yuandian)
Oriza Seed Capital (Oriza Yuandian) investment in Seed Round - Neuexcell Therapeutics
Foothill Ventures
Foothill Ventures investment in Seed Round - Neuexcell Therapeutics
Innoangel Fund
Innoangel Fund investment in Seed Round - Neuexcell Therapeutics
BioVenture
BioVenture investment in Seed Round - Neuexcell Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-18 | NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer |
| 2021-08-23 | NeuExcell Therapeutics names Russ Addis as Vice President, Research |
Official Site Inspections
http://www.neuexcell.com Semrush global rank: 4.95 M Semrush visits lastest month: 1.72 K
- Host name: cloudproxy10156.sucuri.net
- IP address: 192.124.249.156
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neuexcell Therapeutics"
NeuExcell
NeuExcell Therapeutics is a gene therapy company focusing on neurodegenerative diseases. Our vision is to restore health and improve the quality of life for millions of patients worldwide …See details»
ABOUT US - NeuExcell
NeuExcell's innovative technology challenges that doctrine and focuses on regenerating neural tissue. While neurons cannot divide to regenerate themselves, glial cells are a renewable source for generating neurons at the …See details»
NeuExcell Therapeutics - Crunchbase Company Profile …
View contacts for NeuExcell Therapeutics to access new leads and connect with decision-makers. NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair …See details»
NeuExcell Therapeutics - LinkedIn
NeuExcell Therapeutics is a gene therapy company focusing on improving the lives of patients suffering from neurodegenerative diseases. We have discovered a disruptive technology that focuses...See details»
OUR TEAM - NeuExcell
Innovative and inspirational team with decades-long experience in senior management roles.See details»
Cracking the neuroregeneration code - Nature
One company, NeuExcell Therapeutics, may have unlocked the method for regenerating neural tissue. The company’s neuroregenerative gene therapy platform is built around transcription factor-based...See details»
Novel Gene Therapy Generated New Functional …
Mar 12, 2020 · NeuExcell Therapeutics, Inc. is a preclinical gene therapy company based in State College, Pennsylvania, focusing on neurodegenerative diseases. NeuExcell developed a disruptive...See details»
NeuExcell Therapeutics - Funding, Financials, Valuation & Investors
NeuExcell Therapeutics is a medical organization that provides diagnostic and research services.See details»
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To ...
Aug 30, 2021 · NeuExcell is a privately held early-stage gene technology company, with its headquarters in Pennsylvania, USA and Shanghai, China. Its mission is to improve the lives of …See details»
FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics …
Sep 13, 2021 · NeuExcell is a privately held early-stage gene technology company headquartered in Pennsylvania, USA. Its mission is to improve the lives of patients suffering from neuro …See details»
CAREERS - neuexcell.com
NeuExcell has established its corporate headquarters in Philadelphia. We are committed to building a world-class team to advance our mission of developing life-changing therapies. We …See details»
NeuExcell Therapeutics and Spark Therapeutics Announce …
Sep 7, 2021 · NeuExcell is a privately held early-stage gene therapy company headquartered in Pennsylvania, USA. Its mission is to improve the lives of patients suffering from neuro …See details»
NeuExcell, Spark to Develop Gene Therapy for Huntington’s
Oct 12, 2021 · Under the terms of the agreement, Spark, a member of the Roche Group, will have access to NeuExcell’s gene therapy platform and hold an option to license the exclusive global …See details»
FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics …
Sep 13, 2021 · NeuExcell is a privately held early-stage gene technology company headquartered in Pennsylvania, USA. Its mission is to improve the lives of patients suffering from neuro …See details»
FDA Grants Orphan Drug Designation to AAV Gene Therapy …
Dec 20, 2023 · NXL-004 (NeuExcell Therapeutics, Philadelphia, PA) has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA). NXL-004 is the first …See details»
NEWS AND MEDIA - NeuExcell
Philadelphia, PA., May 4, 2023– NeuExcell Therapeutics (www.neuexcell.com), a gene therapy company focusing on neurodegenerative diseases, has announced a $15+ million Series Pre …See details»
NeuExcell Therapeutics Announces Successful Dosing of First …
Mar 22, 2024 · NeuExcell Therapeutics, a leading biotechnology company focused on in vivo neural regenerative therapies, announces the successful dosing of the first patient with the first …See details»
SCIENCE - NeuExcell
NeuExcell's in situ neuroregeneration technology uses AAV as a vector to locally deliver neural transcription factors to specific regions. The neurons derived from astrocytes are the correct …See details»
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted …
Dec 18, 2023 · The FDA granted Orphan Drug Designation ("ODD") to NXL-004, an investigational AAV gene therapy product being developed by NeuExcell Therapeutics Inc., for …See details»
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted …
Dec 18, 2023 · NXL-004 is an innovative treatment based on the groundbreaking astrocyte-to-neuron ("AtN") conversion platform developed by Professor Gong Chen. It has shown good …See details»